A major challenge in analyzing cancer patient transcriptomes is that the tumors are inherently heterogeneous and evolving. We analyzed 214 bulk RNA samples of a longitudinal, prospective ovarian cancer cohort and found that the sample composition changes systematically due to chemotherapy and between the anatomical sites, preventing direct comparison of treatment-naive and treated samples. To overcome this, we developed PRISM, a latent statistical framework to simultaneously extract the sample composition and cell type specific whole-transcriptome profiles adapted to each individual sample. Our results indicate that the PRISM-derived composition-free transcriptomic profiles and signatures derived from them predict the patient response better than the composite raw bulk data. We validated our findings in independent ovarian cancer and melanoma cohorts, and verified that PRISM accurately estimates the composition and cell type specific expression through whole-genome sequencing and RNA in situ hybridization experiments. PRISM is freely available with full source code and documentation.
7.1 · 10 −3 ), but no difference between the primary and the relapsed samples (p rc ∈ [0.070, 0.72]), when accounting for the anatomical site. We also quantified, for the first time, the impact of anatomical sites to the sample composition: omentum, ovary, and peritoneum have similar composition (p rc ∈ [0.066, 0.45]), when accounting for the treatment phase differences. Also fallopian tube and uterus are similar with each other, whereas the composition of the ascites samples differs significantly from the solid samples (p rc < 2.9 · 10 −4 ).
Tumor composition differences between the complete response versus progressive disease groups are explained completely by the variations in the treatment phase and anatomical site of the sample (p rc ∈ [0.092, 0.93]), which both contribute independent variation. Consequently, we argue that the composition of a patient bulk tissue sample is a strong confounder, but not a major predictive factor the patient response, necessitating expression profile analysis that controls for the sample composition.
Decomposing bulk RNA-seq data enables cell type specific gene expression analysis. Next, we examined the PRISM-derived cell type specific expression profiles in the cancer, stromal, and immune cells. Fig. 3a shows that the expression levels of well-known cell type specific genes are higher in the respective cell type (p-value p m < 1.9 · 10 −15 for equal medians in a rank-sum test), and that the cell type specific expression is enriched in the decomposed profiles with respect to the composite bulk (p m < 8.0 · 10 −4 ). These imply that, the composite expression signal is also diluted by the presence of non-specific signals, masking cell type specific phenotypic changes. The cell type specificity of known housekeeping genes 19 is significantly lower than other genes with comparable expression level (p m < 5.2 · 10 −6 ), suggesting the specificity is well-founded.
We performed variance analysis to quantify the extent to which the composite expression profiles are corrupted by the sample composition. In the composite data, ∼40 to 90% (p rc < 2.7·10 −4 ) of the variation is explained solely by the composition, as shown Fig. 3b . Interestingly, the effect varies between the genes. For instance, KIF1A expression has only 16% compositional effect, whereas C1R expression is explained by 77% by the composition, and the immune specific genes, e.g. PPBP, are more susceptible of having a cancer or fibroblast component. This suggests that the immune cell gene expression patterns are more dependent on the microenvironment composition than that of the other cell types. Consequently, previous analyses performed on patient tissue samples without accounting for the compositional factors likely remain useful, but may be biased towards findings in less compositionally affected gene sets.
When analyzing the PRISM-derived cell type specific profiles, only ∼0 to 15% of variation is explained by the composition, as shown in Fig. 3b . This indicates that PRISM can eliminate the confounding effect of composition variation in the decomposed signals and enrich the sample specific signal of the constituent cell types, as intended. Further, the remaining variation is captured by the cell type specific decomposed expression profiles (p rc < 1.8 × 10 −8 ; see Fig. 3b ), suggesting that the signal passing trough to the decomposed cell types is both a significant explanatory factor and that it well captures the sample specificity of the original composite bulk sample.
We also verified that the cell type specificity of expression patterns is not limited to individual genes, but is reflected in pathway activity estimates as well. We derived gene set enrichment analysis (GSEA) scores 20 for the NCI Pathway Interaction Database (NCI-PID) 21 pathways from both the composite and decomposed data as shown in Fig. S8 . While most of the differential pathway scores apper to originate from cancer cells, a significant effect is contributed by fibroblasts and immune cells depending on the pathway. For example, the NOTCH, FOXM1, and HIF1A pathway scores appear to originate from the cancer cells (<5.3% from other sources); RB1, PI3KCI, and FANCONI mostly from a combination of cancer and immune cells (<3.3%); FGF from cancer and stroma (<1.1%); and IL4 and IL23 mostly from immune cells (<2.9%), as shown in Fig. 3c and Fig. S9 . Accordingly, the pathway scores using the decomposed profiles yield higher GSEA scores, indicating that the decomposition allows performing pathway analysis at a finer level of detail, by accounting for the compositional variation and removing the nuisance cell components, as suggested by Fig. 3b . The results were confirmed in the TCGA ovarian cancer dataset 7 (see Supplement) .
Validation of the composition estimates. To verify that the composition is accurately estimated, we compared the PRISM estimates with estimates derived from whole-genome sequencing (WGS)
data. Fig. S6a shows the correlation with ASCAT 22 purity estimates from the corresponding WGS data. The correlation is 77% (p-value p lc < 6.3 · 10 −17 for no linear correlation in a t-test). Further, we verified that the composition can be accurately estimated in other datasets and cancer types. Thus we applied PRISM on the TCGA ovarian cancer 7 bulk RNA sequencing data using our single-cell data; and to the TCGA skin cutaneous melanoma 8 bulk RNA sequencing data using the single-cell data from Tirosh et al. 23 and compared with the estimates from TCGA clinical data (immunohistochemistry) 7, 8 , ABSOLUTE 24 (whole-genome sequencing), and LUMP 6 (methylation 450k array) from Aran et al. 6 (see Supplement) . Finally, we verified that comparable composition estimates are obtained by using a single-cell panel derived from a different sequencing platform and when holding out the matching patients (see Supplement).
Validation of cell type specificity of expression profiles. We performed RNA-ish experiments to verify that the PRISM decomposed profiles are indeed expressed differentially in cancer, stromal and immune cells. For this, we selected three genes for each cell type: TRIM29, PARD6B, KIF1A
(cancer cell specific), C1R, COL1A2, NAALADL2 (fibroblast), RNASE6, GPR34, and C3AR1 (immune). The genes were selected to have high expression in the specific cell type ( Fig. 3 ) and a significant difference between the complete response and progressive disease groups. As show in Fig. 4 , RNA-ish validation was done with samples from seven HGSOC patients with matching bulk RNA-seq data, all nine genes being highly expressed in the PRISM predicted cell type (p m < 10 −8 ), except for NAALADL2.
Decomposed RNA profiles predict patient response. The PRISM analysis revealed several genes with expression level differences between complete response and the progressive disease patients groups, of which the most prominent are shown in Fig. S7 . Cancer cell specific genes TRIM29, PARD6B, and KIF1A were found to be upregulated in the progressive disease group, while the fibroblast specific C1R, COL1A2, and NAALADL2, and immune specific RNASE6, GPR34, and C3AR1 are downregulated in the progressive group (p m < 6.5 · 10 −8 ). In the RNA-ish data, the difference was significant for six genes (KIF1A, C1R, COL1A2, RNASE6, GPR34, and C3AR1), for TRIM29 and PARD6B the trend was opposite, and for NAALADL2 was inconclusive.
For KIF1A, C1R, and GPR34, we divided the 214 bulk RNA samples into the bottom 50% and top 50% groups by the expression level to predict the time to progression of the disease. As suggested by the differences between the complete response and progressive disease groups, we found that a high level of KIF1A in the cancer cell specific profile and low levels of C1R and GPR34 in the fibroblast and immune specific profiles, respectively, confer less effective treatment and more rapid recurrence of the cancer. As shown in Fig. 5 , this difference is not visible in the composite bulk signal. We verified that a similar association exists in the decomposed TCGA ovarian cancer 7 data for KIF1A, C1R (p-value p h < 6.6 · 10 −5 for equal hazards in a log-rank test), and GPR34 (p h = 0.07) regarding overall patient survival (see Fig. S15 ). While the trend is also visible in the composite bulk data for KIF1A (p h = 9.2 · 10 −5 ), the results for C1R are not (p h = 0.20). In general, the survival associations are more significant for the decomposed data for the selected genes and at the whole-transcriptome scale in both ovarian cancer and in skin cutaneous melanoma (see Supplement).
KIF1A, C1R and GPR34 have not been associated with HGSOC survival earlier. KIF1A overexpression has been associated with cancer tissue in endometrial cancer 25 and it confers docetaxel resistance in breast cancer cell lines 26 . Peptidase S1 protein family genes, such as C1R, are often expressed in the stroma and endothelium of various malignant tumors 27, 28 , and are associated with innate immune response activation, inducing phagocytosis, among various functions 28, 29 . GPR34 is expressed primarily in specific immune cells 30 and has been shown to be required for adequate immune response in mice 31 ; it has been shown to be differentially expressed to the non-cancerous tissue in at least six different cancer types 30 . The expression differences of these genes and their relevant function in other cancers warrants further study of these genes as prognostic and/or therapeutic targets.
Several studies have reported gene expression signatures in HGSOC and other cancers. As these are predominantly derived from bulk RNA-seq data, we tested their robustness in PRISM decomposed profiles. We derived HGSOC subtype estimates using the CLOVAR method 32 , which classifies the samples into differentiated (DIF), immunoreactive (IMR), mesenchymal (MES), or proliferative (PRO) subtypes from both the composite and decomposed RNA profiles. Our results indicate that within the HGSOC subtypes, the IMR subtype highly depends on the immune cell frequency alone (77% correlation; see Fig. S10 ) and the MES subtype on fibroblasts (84%). DIF and PRO subtypes appear to originate from the cancer cells and feature weaker correlation with the composition (p rc = 0.49 and 0.80, respectively), suggesting that these subtypes likely reflect phenotypic differences in the cancer cells, unlike the IMM and MES subtypes. The results were consistent between the our longitudinal and the TCGA ovarian cancer datasets.
In the TCGA dataset we found that deriving the subtypes in the absence of fibroblast and immune signals yields a significantly better separation in the overall survival (p h < 4.5 · 10 −3 ) than from the composite bulk data (p h = 0.15), as shown in Fig. 5 . To exclude the possibility that the gene expression signatures are unstable in HGSOC only, we analyzed gene expression signatures in TCGA skin cutaneous melanoma 8 dataset using the expression-derived subtypes 8 . Here, the "immune" subclass reflects mostly immune cell frequency (77% correlation, p rc < 3.0·10 −2 ), while the MITF-low and keratin subtypes represent likely phenotypic differences between the cancer cells. Again, after removing the confounding immune component and the compositional variation, the patient classification predicts overall survival much better (p h = 4.7 · 10 −3 versus 0.022).
In general, our results indicate that some of the previously reported cancer subtypes obtained by clustering composite expression data are explained by the sample composition variation alone. This is in line with a previous report in head and neck cancer 33 . While the composition may be indicative of patient survival (e.g. high immune content tends to correlate with better survival), our results show that the patient response and survival can be more accurately predicted by subtyping the cell type specific signals separately.
Discussion
We developed a statistical framework, PRISM, for the analysis of heterogeneous RNA mixtures, and showed how it can be exploited for extracting the composition and the bulk-adapted wholetranscriptome profiles for each constituent cell type from each individual bulk RNA sample. By analyzing 214 longitudinal HGSOC samples, we showed that the tumor composition varies systematically with the treatment phase and the anatomical location, posing a challenge in personalized transcriptomic analysis. We showed that these challenges can be overcome with PRISM, which accurately estimates cell type specific expression profiles, which can serve as better predictors of patient response than bulk RNA-seq data. Importantly, analysis of 308 TCGA ovarian cancer, and 474 TCGA skin cutaneous melanoma samples agreed with these findings.
The main limitation of PRISM is that a heterogeneous sample of single-cell data from each cell type involved is required for consistent performance, which can be a problem if the reference and the analysis datasets are stratified according to different criteria. However, as we have shown, good performance can be expected without matching data as long as the single-cell data is not inherently biased. Further, as a statistical method, the expression profile estimates for infrequent cell types can be inaccurate, which may limit the analysis of (but not controlling for) stromal and immune cell subtypes. These points may warrant further investigation, but we expect that the issues are mitigated in the future as single-cell cataloging efforts move forward.
Precision oncology approach calls for methods that can exploit general statistical patterns in a cohort of a heterogeneous disease, but operate reliably at the individual patient level regardless of the evolving disease state, and adapt to the specifics of that patient, to which PRISM is a response regarding whole-transcriptome analysis of bulk samples. We believe PRISM has direct applications in analyzing transcriptomic data from other diseases that stem from heterogeneous causes and sampling setting, such as other cancer types, and that analysis methods for other genomic domains can benefit from the insights of our approach. RNA-seq preprocessing. Bulk RNA sequencing reads were preprocessed using SePIA 36 pipeline within the Anduril framework 37 . Read pairs were trimmed using Trimmomatic (version 0.33) 38 as follows: i) the first 12 bases were cropped due to uneven per base sequence content; ii) any leading bases with a quality score lower than 20 and any trailing bases with a quality score lower than 30 were removed; iii) the reads were scanned with a 5-base wide sliding window, cutting when the average quality per base drops below 20; iv) resulting sequences shorter than 20 bp were discarded. Trimmed reads were aligned to the GRCh38.d1.vd1 reference genome with GENCODE v25 annotation using STAR (version 2.5.2b) 39 , allowing up to 10 mismatches, and all alignments for a read were output. Gene level effective counts (we found these to be more accurate than the raw read counts) were quantified using eXpress (version 1.5.1-linux x86 64) 40 .
Methods
For the single-cell sequencing data, the raw base call (BCL) files were processed, including demultiplexation, alignment, barcode assignment and UMI quantification, with CellRanger (ver- Modeling RNA expression data. We assume that latent cell type specific RNA counts Z ilj exist, and can be approximated by a scaled Poisson distribution, i.e. T il Z ilj ∼ P(T il X ilWlj G j ), where the index i ∈ Z [1,m] runs over the m genes, l ∈ Z [1,k] over the k cell types, and j ∈ Z [1,n] over the n samples, and X il ∈ R ≥0 represents the cell type specific average expression profile,
is the dispersion (specific to each cell type and gene),W lj ∈ R ≥0 the convex composition, and we assume that a cell type (and bulk specific) expression profiles (X il , T il ) exist, as specified in the previous section, composing the bulk, i.e. T il Z
(1)
and being similar to the single-cell data, i.e. T il Z
where y (0) and Y (1) and the single-cell and bulk data, respectively, Z (0) and Z (1) their latent random state,w (0) andW (1) their convex composition, and G (0) and G (1) the sample scale factors. Again, i runs over the genes, l over the cell types, j over the single-cell profiles, and r over the bulk replicates (typically r = 1). As T il can vary, the decomposition will weigh in the genes that are informative in discriminating the cell types. 
st. |Ω i | = α m, revealing a global relative scaling factor G j for each single-cell sample.
Discovering constituent phenotypes. In the decomposition, the composition W (0) of the reference profiles (i.e. single-cell data) can be either preset or let vary freely. To facilitate more complex analyses, we also devised a hierarchical clustering process that exploits our model and reveals the cell types such that a single common bulk-independent consensus can be reached. The process is governed by the same model, i.e. T il Z
ilj , for the single-cell data Y (0) but results in a binary compositionW (0) built up agglomeratively. This procedure is more stable against the multiple optima than an iterative algorithm, and allows selecting the optimal number of components using statistical means, such as Bayesian information criterion (BIC) unlike general-purpose clustering algorithms. ... 
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